Aim We aimed to isolate and propagate internal and external anal sphincter progenitor cells from the human anal sphincter, with or without radiotherapy, for tailored cell therapy of faecal incontinence.
Methods Sphincter progenitor cells were isolated from normal internal and external anal sphincters collected from 10 patients with rectal cancer who had undergone abdominoperineal resection with (n = 6) or without (n = 4) preoperative chemoradiotherapy. The isolated cells and differentiated muscle fibres were identified using immunofluorescence assay, western blotting and reverse transcription polymerase chain reaction (RT-PCR). The proliferation of progenitor cells with and without radiotherapy was compared by quantitative 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay.
Results The immunofluorescence assay before differentiation confirmed that the internal anal sphincter progenitor cells expressed CD34 and neural-glial antigen 2 (NG2), whereas the external anal sphincter progenitor cells expressed CD34 and PAX7. After differentiation, the internal anal sphincter progenitor cells expressed desmin, calponin and a-smooth muscle actin, whereas the external anal sphincter progenitor cells expressed desmin, myogenic factor 4 and myosin heavy chain. The differential expression profiles of both cell types were confirmed by western blotting and RT-PCR. MTT assays showed that the viability of internal and external anal sphincter progenitor cells was significantly lower in the radiotherapy group than that in the nonradiotherapy group.
Introduction
Faecal incontinence (FI) is considered a benign condition without life-threatening sequelae. However, it adversely affects all aspects of an individual's life, and the optimal treatment remains unclear [1] . FI is usually caused by damage to the anal sphincter or nerve complex following trauma, including obstetric injury or anorectal interventions. Although an insufficiency of skeletal muscle cells in the external anal sphincter (EAS) contributes to FI, the critical factor for FI is functional loss of the fatigue-resistant smooth muscle in the internal anal sphincter (IAS), which plays a role in the maintenance of normal anal canal tone [2, 3] .
Recovery of anal function with various autologous cell-based therapies and tissue engineering has recently been reported, although some limitations have hampered the restoration of incontinent sphincters, including the functional connection of the graft to the host nervous system, the ingrowth of new blood vessels and the attachment of implanted cells [1, 4, 5] . A functional in vitro animal model of the IAS demonstrated the feasibility of a bioengineered, intrinsically innervated human IAS construct with viable myogenic and neuronal components [2, 3] . However, the difficulties in scaling these bioengineered IAS constructs to the size of the human anal sphincter have not been adequately overcome [6] . In addition, the therapeutic potential of autologous myoblasts [4, 5, 7] , muscle progenitor cells [8] , muscle-derived stem cells [1] , isolated smooth muscle cells [2, 3, 9, 10] , adipose-derived stem cells [11, 12] and combined biomaterials [13, 14] still requires convincing evidence-based support for clinical application in this type of regenerative medicine.
No studies have differentially isolated and cultured smooth and skeletal muscle cells from the human anal sphincter. Additionally, in previous studies, whether radiotherapy adversely affected anorectal function in patients with rectal cancer was unclear in terms of cell proliferation and cell viability, while anorectal physiological or morphological studies of nerve or muscular injury showed anorectal dysfunction induced by radiotherapy [15] [16] [17] . Therefore, we sought to isolate IAS and EAS progenitor cells as potential tools for tailored cell therapy for FI and to investigate the impact of radiotherapy on the anal sphincter by using human anal sphincters from patients treated with or without radiotherapy.
Methods

Collection of human IAS and EAS tissues
Normal IAS and EAS muscles were collected from 10 patients with rectal cancer who had undergone abdominoperineal resection with (n = 6) or without (n = 4) preoperative chemoradiotherapy ( Table 1 ). The median age was 70 years (range 49-80), and the sex ratio of men to women was 9:1. The median tumour height was 2.75 cm (range 0-5 cm) from the anal verge. Six of the patients were diagnosed with cT3-4N0-2 lesions based on MRI and had received preoperative long-course concurrent chemoradiotherapy at a dose of 50.4 Gy; 45 Gy was administered in 25 fractions to the pelvis, and a 5.4 Gy boost was administered in three fractions to the primary tumour [18] . The study was approved and supervised by the Institutional Review Board of Seoul National University Bundang Hospital (Seongnam, Korea), and all patients provided informed consent for tissue harvesting. The muscle samples, harvested from normal tissues located more than 1 cm from the gross tumour, were divided into IAS and EAS muscles, and strips of approximately 1 9 1 mm 2 were cut. Fresh IAS and EAS tissues were examined histologically with haematoxylin and eosin staining, confirming that the IAS was composed of smooth muscle cells (Fig. S1A ), whereas the EAS was composed of striated muscle cells (Fig. S1B ). Cell isolation and differentiation IAS progenitor cells were isolated from the IAS as previously described [19, 20] with some modifications. Briefly, the muscle tissues from the IAS were plunged into a 50-ml conical tube containing chilled KrebsHenseleit buffer (Sigma-Aldrich, St Louis, Missouri, USA) with 2% penicillin/streptomycin (PS). Enzymatic digestion was performed in 0.1% collagenase type II (Gibco, Waltham, Massachusetts, USA) containing 0.01% soybean trypsin inhibitor (Gibco) at 37°C for 2 h in a CO 2 incubator. After centrifugation for 10 min at 25°C (1300 g), the solution was replaced with fresh Krebs-Henseleit buffer containing 0.1% collagenase type II and 0.01% soybean trypsin inhibitor. After the second digestion period, the samples were centrifuged for 10 min at 25°C (1300 rpm). The cell pellets were washed three times to remove the collagenase and were then resuspended in smooth muscle growth medium (SmGM-2) (Lonza, Basel, Switzerland) for 5 days. Cell differentiation was induced by replacing the growth medium with 75% Dulbecco's modified Eagle's medium (DMEM) (Gibco) containing 20% Medium 199 (Gibco), 7% horse serum and 1% PS. EAS progenitor cells, which are differentiated into a specific type of EAS, were isolated from the EAS as previously described [21, 22] . Briefly, the EAS muscle tissues were plunged into a 50-ml conical tube containing chilled DMEM with 1% PS. The cut tissues were transferred into 50-ml conical tubes containing 10-15 ml of DMEM with 1% PS. After fitting a loose cap, the tubes were incubated in a CO 2 incubator at 37°C for 48 h. After centrifugation for 5 min at 25°C (1200 rpm), the supernatant was removed and the samples were enzymatically digested with 10 ml of 0.1% collagenase type II (Gibco) and 0.01% dispase (Gibco) at 37°C under 5% CO 2 for 1 h in an orbital shaker. After centrifugation for 5 min at 25°C (1200 rpm), the cell pellets were washed three times to remove the collagenase and were resuspended in DMEM containing 10% horse serum and 1% PS. The unattached cells in the supernatant were transferred to a new dish after incubation for 2 h; this process was repeated twice. The floating cells were incubated in another dish for 5 days. The isolated EAS progenitor cells were grown in tissue culture dishes with skeletal muscle growth medium (SkGM-2, Lonza) containing supplement (Lonza) until the cells reached~70% confluence [12] . The growth medium was then replaced with DMEM/F12 (1:1) (Gibco), 2% horse serum and 1% PS at 37°C in a CO 2 incubator to allow the cells to differentiate.
Immunofluorescence assay
Monoclonal antibodies (all from Abcam, Cambridge, UK) were used to detect specific biomolecular markers before and after cell differentiation (Table 2 ). For the immunofluorescence assay, the cells were fixed for 20 min in 4% paraformaldehyde in phosphate buffered saline (PBS, pH 7.4), washed and incubated for 90 min at 37°C in PBS containing 0.3% Triton X-100 (SigmaAldrich). The tissue sections were then deparaffinized, rehydrated and processed to block any endogenous peroxidases. The fixed cells were diluted with 1 ml of PBS containing Triton X-100 and then with normal goat serum or normal horse serum. These cells were incubated in culture medium containing a monoclonal antibody at À4°C for 24 h. After the cells were tagged with a secondary antibody (Alexa-Fluor-488-conjugated goat anti-mouse IgG antibody or Alexa-Fluor-594-conjugated goat anti-rabbit IgG antibody) (Jackson ImmunoResearch, Baltimore, Pennsylvania, USA), the nuclei were counterstained with 4 0 ,6-diamidino-2-phenylindole (IBSC, New York, USA). Negative-control staining was performed for each marker by omitting the primary antibody. The expressed markers were examined by fluorescence microscopy (AxioVision 4; Zeiss, Jena, Germany).
Western blotting
To confirm the expression of protein markers during the proliferation of the progenitor cells, we used western blotting to detect several markers, including CD34, neuralglial antigen 2 (NG2) and PAX7 before cell differentiation and desmin, myogenic factor 4 (MYOG), myosin heavy chain (MyHC) and alpha-smooth muscle actin (a-SMA) after cell differentiation (Abcam). The total protein concentrations were assessed using the bicinchoninic acid method (Bradford assay) with a protein assay kit (Bio-Rad, Hercules, California, USA). After loading 10-15 lg of protein into each lane of a precast 12.5% Tris-HCl gel (Ready Gel; Bio-Rad), the proteins were separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis and transferred to membranes. The membranes were blocked with 5.0% skim milk and Tris-buffered saline containing Tween 20 (TBST) (BioPlus, Yongin, Gyeonggido, Korea) for 90 min. The membranes were then incubated with the primary antibodies at 4°C for 24 h. After incubation, the membranes were rinsed to remove any unbound primary antibody and then incubated with the secondary antibody in TBST for 90 min at room temperature. The band densities were determined with densitometry after scanning and were evaluated with ImageJ software (Kodak, M35; Rochester, New York, USA).
Reverse transcription polymerase chain reaction (RT-PCR)
RT-PCR was performed before and after differentiation of the two types of cells. Specific primers for RT-PCR were designed to amplify the transcripts of the marker proteins identified by western blotting (Bioneer, Deajeon, Korea). The cells were homogenized in TRIzol Reagent (iNtRON, Sungnam, Gyeonggi-do, Korea) to extract total RNA before and after differentiation. Complementary DNA (cDNA) was synthesized from total RNA with random primers and the SuperScript III One-Step RT-PCR System (Invitrogen, Waltham, Massachusetts, USA) and was amplified with Solg TM 2 9 Taq PCR Smart Mix 2 (Solgent, Deajeon, Korea).
Viability of progenitor cells
The proliferation of the progenitor cells was assessed according to sphincter muscle type and exposure to radiotherapy. A 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay (Amresco, Cleveland, Ohio, USA) was used to assay cell viability. The control group contained nonirradiated cells, which were compared with irradiated cells from IAS and EAS muscles. In the MTT assay, progenitor cells were seeded in six-well plates, incubated at 37°C and washed twice with PBS, and then 5 mg/ml of MTT in PBS was added to each well for 4 h. After removing the MTT solution, solubilization solution (dimethyl sulfoxide; Daejung, Siheung, Gyeonggi-do, Korea) was added to each well to dissolve the formazan crystals. The absorbance was measured at 550 nm with a paradigm microplate reader (SpectraMax Plus 384 microplate reader; Molecular Devices, Sunnyvale, California, USA). After 24, 48, 72, 96 and 120 h, the cells were diluted with a working solution of dimethyl sulfoxide and counted to construct a growth curve.
Statistical analysis
The Mann-Whitney test was used to compare the cell viability in the irradiated and nonirradiated groups after gross examination. P values < 0.05 were considered to be statistically significant. All calculations were performed using SPSS software (ver. 21.0) for Windows (IBM Corporation, Armonk, New York, USA).
Results
Isolation and differentiation of IAS and EAS progenitor cells
IAS progenitor cells were successfully isolated from eight of the 10 patient samples but not from the two patients who had undergone radiotherapy (patients 1 and 3). EAS progenitor cells were isolated from all patient samples. These IAS and EAS progenitor cells proliferated continuously in the culture medium (Fig. 1a, b, d and e). Seven days after being transferred to differentiation medium, the IAS progenitor cells had differentiated into cells with morphological attributes consistent with the smooth muscle cell type (Fig. 1c) . Unlike the IAS progenitor cells, the EAS progenitor cells differentiated into cells with morphological attributes consistent with the skeletal muscle cell type (Fig. 1f) .
Characterization of the IAS and EAS progenitor cells
Eight monoclonal antibodies and a negative control were used to characterize the IAS and EAS progenitor cells. Differences were observed in the expression profiles according to the anal sphincter muscle type and the differentiation status of the progenitor cells. The immunofluorescence assay before differentiation
showed that the IAS progenitor cells expressed CD34 and NG2, whereas the EAS progenitor cells expressed CD34, NG2 and PAX7. After differentiation, the IAS progenitor cells were positive for desmin, calponin and a-SMA, whereas the EAS progenitor cells were positive for desmin, MYOG and MyHC (Fig. 2) . Western blotting before differentiation showed that the IAS progenitor cells expressed CD34 and NG2, whereas the EAS progenitor cells expressed CD34 and PAX7 (Fig. 3a) . After differentiation, the expression profiles determined by western blotting were identical to those observed in the immunofluorescence assay. The expression profile of the irradiated anal sphincter muscle cells was identical to that of the nonirradiated group determined by western blotting. We also performed RT-PCR using primers designed to amplify the transcripts of the protein markers detected by western blotting (Fig. 3b) . 
Viability of progenitor cells
The MTT assays showed that the viability of the IAS progenitor cells was lower in the irradiated group than in the nonirradiated group at 24 h (12.1% vs 6.8%, respectively; P = 0.040), 48 h (12.3% vs 6.6%, respectively; P = 0.024), 72 h (12.4% vs 6.5%, respectively; P = 0.019) and 96 h (12.2% vs 6.7%, respectively; P = 0.031), although not at 120 h (11.3% vs 7.6%, respectively; P = 0.161) (Fig. 4a) . The viability of the EAS progenitor cells was also lower in the irradiated group than in the nonirradiated group at 48 h (12.5% vs 6.4%, respectively; P = 0.014), 72 h (13.7% vs 5.2%, respectively; P = 0.001), 96 h (13.7% vs 5.2%, respectively; P = 0.001) and 120 h (13.6% vs 5.3%, respectively; P = 0.001) (Fig. 4b) .
Discussion
This study demonstrates the differential isolation of IAS and EAS progenitor cells from the human anal sphincter. The differential harvest of human anal sphincter cells was confirmed when the IAS and EAS progenitor cells underwent distinct differentiation processes, displaying different profiles at the mRNA, cDNA and protein levels before and after differentiation. We also confirmed that the viability of the IAS and EAS progenitor cells is decreased by radiotherapy. These outcomes imply that, in patients with FI, regenerative medicine using IAS or EAS progenitor cells can be used to tailor cell therapy according to the sphincter muscle type involved. Although autologous myoblasts derived from the pectoralis muscle [4] , muscle progenitor cells from the quadriceps muscle [8] and skeletal-musclederived stem cells from the gastrocnemius muscle [1] or quadriceps muscle [5] may be suitable for patients with a deficiency of the anal sphincter, the myoblasts could be limited to IAS, which is composed of smooth muscle characterized by tonic muscle that remains contracted at rest, with small-amplitude slow contractions and slow relaxation. Furthermore, muscle-derived stem cells or Figure 2 Immunofluorescence assay. After the isolation of IAS and EAS progenitor cells, the muscle types were assessed before and after differentiation using a negative control (a1-a8 and d1-d8) and primary antibodies. Expression profiles of CD34 (b1) and NG2 (b2) in IAS progenitor cells before differentiation and of desmin (c4), calponin (c6) and a-SMA (c8) after differentiation; expression profiles of CD34 (e1), NG2 (e2) and PAX7 (e3) in EAS progenitor cells before differentiation and of desmin (f4), MYOG (f5) and MyHC (f7) after differentiation. NG2, neural-glial antigen 2; MYOG, myogenic factor 4; MyHC, myosin heavy chain; a-SMA, alpha-smooth muscle actin.
progenitor cells differentiate into heterogeneous cells regardless of the sphincter muscle type required by the FI patient [23] . With our strategy, smooth muscle progenitor cells can be used to treat the IAS, and skeletal muscle progenitor cells can be used to treat the EAS; thus, the specific muscle involved in the individual FI patient can be targeted according to the aetiology [24] . This study showed that multiple markers, including CD34, NG2, PAX7, desmin, calponin, a-SMA, MYOG and MyHC, define a cellular hierarchy and allow the selection of specific subpopulations of cells. Using MTT assays, we found differences in the viability of IAS and EAS progenitor cells during their proliferation, whereas previous studies were unclear regarding the final differentiation status of autologous progenitor or derived cells after their isolation [4, 8] .
Until recently, no definitive evidence at the cellular level has indicated that radiotherapy causes poor anorectal function. This study quantified the IAS and EAS progenitor cells of the human anal sphincter at the cellular level, whereas previous studies of FI have focused on measurement of the anal sphincter pressure, surveillance through questionnaires or morphological studies after nerve or muscular injury [15] [16] [17] . In this study, MTT assays showed that the viability and proliferation of IAS and EAS progenitor cells were lower in the irradiated group than in the nonirradiated group. These findings may explain why IAS progenitor cells were successfully isolated in only four of six patients (67%) after radiotherapy in our study, which was lower than the success rate (100%) in patients treated without radiotherapy. The quantitative differences in the proliferation rates of these cells indicate that the restorative capacity of the tissues may be affected by irradiation of the sphincter, which should be considered in tailored cell therapy.
We have considered the potential utility of allogeneic implantation using human IAS or EAS progenitor cells collected from the normal anal sphincters of living or cadaveric donors, although this possibility may be limited by immunological barriers. A previous study demonstrated the survival of muscle-derived progenitor cells without immunosuppressive agents because the expression of major histocompatibility complex class I was downregulated in the progenitor cells [25, 26] . These hypoimmunogenic properties of progenitor cells may reduce the occurrence of apoptosis after transplantation, thus enhancing graft survival [27] . Several studies have investigated the applicability of immunosuppressive drugs to prevent cell rejection, and some adjustments were applied to reduce the risk of drug toxicity and any negative effects [28, 29] . Allogeneic cell transplantation for FI may be feasible in the future with modifications to established immunosuppressive protocols. In addition, adipose-tissue-derived mesenchymal stem cells, which have pluripotent abilities when inflammatory responses are suppressed, may have potential benefits for FI [12, 30] .
Current regenerative cell therapies are inefficient, probably because the implanted cells are lost when cell attachment, migration or differentiation fails [31, 32] . Moreover, cell therapy alone for FI is limited to restoration of a human-sized anal sphincter [13] . In previous studies, we demonstrated the feasibility of basic fibroblast growth factor loaded biocompatible polycaprolactone (PCL) beads and myoblasts for functional improvement of anal sphincter defects in an animal model of FI [13, 14] . Tailored cell therapy with IAS or EAS progenitor cells using injectable biomaterial (PCL) beads warrants consideration in the future. This study had several limitations. First, our sample size did not have sufficient statistical power, which could have caused type II errors. This resulted from practical constraints because the number of available patients who underwent abdominoperineal resection for rectal cancer was fewer than that required. Second, we did not show the longevity of the cells or the differentiated myotubes in culture, nor did we show functional differences according to the age of the cell donor. The sphincter complex is known to degenerate with age and menopause [33] , so these factors will be investigated in a future study using advanced techniques [34] . Third, our study did not show in vivo experimental data from a suitable animal model and was not supported by fluorescence-activated cell sorting. An in vivo experimental study would support the clinical potential of the progenitor cell population in the future, which could then be translated into a clinical setting.
In conclusion, this study shows the differential harvest of IAS and EAS progenitor cells from the human anal sphincter. Smooth or skeletal muscle progenitor cells cultured from the human IAS or EAS, respectively, may be useful to target defects in the corresponding sphincter regions in cell therapies tailored to the aetiology of FI.
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